Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
161Tb-PSMA-I&T in mCRPC
NCT07621692Phase 1Recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 1, open-label trial of [161Tb]Tb-PSMA-I&T in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by National Taiwan University Hospital. Primary endpoint: Treatment-emergent adverse events at 36 weeks. Started Jan 2026; status: recruiting.
02
Drugs
[161Tb]Tb-PSMA-I&T
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07621692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07621692.